Table 2.
Proportion of CD8 + CD38 + HLA-DR+ and CD4+ CD38 + HLA-DR+ T cell subsets in HIV-infected individuals with either primary HIV infection or chronic HIV infection before and after initiation of cART
| Primary HIV infection N = 14 | Early presenters N = 24 |
Late presenters N = 19 | Healthy Controls N = 16 | P | ||
|---|---|---|---|---|---|---|
| % Cells | CD8 + CD38 + HLA-DR+ | |||||
| Baseline | 44.7 (20.3)a,b,d | 22.0 (13.4)b,c,f | 25.6 (21.3)a,c,e | 1.3 (0.8)d,e,f | <.001 | |
| After 6 months of cART | 6.4 (5.6)d | 8.1 (5.5)f | 6.5 (5.3)e | NA | <.001 | |
| After 12 months of cART | 8.9 (8.1)d | 4.0 (1.9)f | 4.7 (2.8)e | NA | <.001 | |
| CD4 + CD38 + HLA-DR+ | ||||||
| Baseline | 5.5 (4.08)a,d | 3.5 (3.0)c,f | 15.5 (15.4)a,c,e | 0.8 (0.6)d,e,f | <.001 | |
| After 6 months of cART | 1.6 (1.4)d | 1.6 (1.3)f | 3.3 (3.4)e | NA | <.001 | |
| After 12 months of cART | 1.6 (0.7)d | 1.1 (0.3) | 2.4 (1.7)e | NA | <.001 | |
Data are shown as mean (SD)
P*: comparing the four groups by using ANOVA if parametric variables or Kruksal-Wallis test if non parametric variables. If significant (<0.05) then t-test if parametric variables or Mann-Whitney if non parametric variables were used to compare two groups. Only significant differences are marked:
aprimary HIV infection vs late presenters
bprimary HIV infection vs early presenters
clate presenters vs early presenters
dhealthy controls vs primary HIV infection
ehealthy controls vs late presenters
fhealthy controls vs early presenters